Company news

Vor Biopharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

February 12, 2025

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

February 2, 2025

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

January 7, 2025

Vor Bio Announces $55.6 Million Private Placement

December 26, 2024

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

December 8, 2024

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

November 11, 2024

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

November 6, 2024

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

September 29, 2024

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

September 4, 2024

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

August 7, 2024

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 8, 2024

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 1, 2024

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

March 19, 2024

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

January 16, 2024

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

November 26, 2023

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

November 8, 2023

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

November 6, 2023

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform

November 1, 2023

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

August 9, 2023

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

July 31, 2023

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform

June 8, 2023

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

June 4, 2023

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

May 10, 2023

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

March 22, 2023

First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

February 15, 2023

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

January 18, 2023

Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference

January 11, 2023

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

December 6, 2022

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

December 6, 2022

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

November 9, 2022

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

October 11, 2022

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

October 10, 2022

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

September 27, 2022

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

August 10, 2022

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

June 9, 2022

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

May 11, 2022

Vor to Participate in Two Upcoming Investor Conferences

May 4, 2022

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

April 24, 2022

Vor Bio Announces Retirement of Chief Medical Officer

April 13, 2022

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

March 13, 2022

Vor Reports Third Quarter 2021 Financial Results and Provides Company Update

November 9, 2021

Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting

November 8, 2021

Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management

October 11, 2021

VOR33 Granted U.S. FDA Fast Track Designation for AML

September 8, 2021

Vor Reports Second Quarter 2021 Financial Results and Provides Company Update

August 8, 2021

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

July 7, 2021

Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs

June 16, 2021

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

June 10, 2021

Vor to Develop Multi-Targeted CAR-Ts with Abound Bio

June 9, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 13 decks. Every deck is listed under its year.